Revenue rose to $534.2 million on top of  tighter overhead control

Durrant Pate/Contributor

R.A. Williams Distributors, a leading distributor of pharmaceutical, nutraceutical, and healthcare products, has delivered a strong first-quarter performance for the 2026/27 financial year, ushering a return to profitability following a challenging 2025.  

Revenue for the first quarter, ended July 31, increased 28% to $534.2 million, up from $417.0 million last year, while the company recorded net profit of $47.9 million, reversing the $1.9 million net loss reported in 2025. Propelling the strong opening quarter was a sharper operational approach, with streamlined supply chain logistics and targeted expense management supporting reliable, high-volume delivery across retail pharmacies and healthcare institutions nationwide. 

As a result, gross profit grew 22% to $230 million, up from $188.2 million in the first quarter of 2025/26, driven by sustained market demand and strategic product mix optimisation. Administrative and general expenses fell to $98.0 million from $105.3 million, bringing total operating expenses to $170.2 million and operating profit to $59.8 million, nearly quadrupling the $15.2 million recorded in Q1 last year.

CEO Audley Reid is pleased with the strong performance, saying, “What we’ve delivered this quarter is a strong reflection of the strength of this business. There were many challenges in the last fiscal year, but we faced them head-on and made calculated changes across the business, including strengthening our distribution network, managing overhead more closely, and refining our commercial focus. Seeing those efforts translate into a return to profitability in the first quarter is encouraging, and we are focused on building on this performance throughout the year.” 

Strengthening financial efficiency 

In strengthening its financial efficiency, R.A. Williams advanced its growth agenda through targeted portfolio diversification. During the quarter, the company entered an exclusive distribution agreement with Cradle of Life Limited, led by International Board Certified Lactation Consultant, Simeca Alexander-Williamson. The maternal and infant health line was launched to the market in August, coinciding with World Breastfeeding Week, and enables R.A. Williams to serve a previously untapped segment of the healthcare market. 

Enhanced expense control also proved instrumental in driving R.A. Williams back into profitability in Q1 of 2026/27. Total operating expenses for the three months ended July 31, 2026, decreased 1.7% to $170.2 million from $173.1 million in the prior-year period, driven largely by a 6.9% reduction in administrative and general expenses to $98.0 million. These structural savings protected operating margins against volume-related direct cost increases as sales expanded. 

Coupled with lower finance costs of $11.9 million, R.A. Williams, based in the old capital of Spanish Town, generated $47.9 million in quarterly net profit, reversing the $1.9 million loss recorded in Q1 last year. Stronger earnings were accompanied by improved cash generation year-on-year, with $53.2 million generated from operating activities in Q1 of 2026/27, compared with a $53.5 million outflow in the corresponding quarter of FY2025/26. 

More financial highlights 

Cash and bank balances increased to $137.9 million from $111.4 million, while earnings per share rose to $0.02 from a loss of $0.00 per share in the prior-year period.  At quarter-end, total assets reached $1.51B, while shareholders’ equity increased to $835.0 million, up from $768.3 million in the corresponding quarter of the previous year. 

The stronger equity base supports the company’s ability to retain earnings, fund inventory growth, and maintain reliable healthcare supply channels nationwide. For Reid, “strong results give us the ability to do more of what matters. They allow us to keep essential medicines available, ensure steady and prompt delivery to pharmacies and healthcare partners, and enable us to serve with greater confidence. At the end of the day, that is what this performance means to us. It puts R.A. Williams in a stronger position to play our part in keeping Jamaica’s healthcare system supplied, and that is something we take great pride in.”